Search -

Displaying 1 - 20 of 22

Sort: Relevancy | Date

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

News Conference News ESC 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

August 29, 2025

Endometriosis and CV Risk: Link Needs Further Attention and Research

News Conference News ESC 2024

Endometriosis and CV Risk: Link Needs Further Attention and Research

Yael L. Maxwell

September 12, 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

August 31, 2024

COP-AF: Colchicine Doesn’t Cut Post-Op AF or Myocardial Injury

News Conference News ESC 2023

COP-AF: Colchicine Doesn’t Cut Post-Op AF or Myocardial Injury

Michael O'Riordan

August 25, 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

August 25, 2023

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

News Conference News ESC 2022

‘Hot’ Plaque on Noninvasive PET May Presage MI, CV Death: PRE18FFIR

August 28, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

News Conference News ESC 2021

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

September 01, 2021

Colchicine in STEMI Fails to Reduce Infarct Size: COVERT-MI

News Daily News ESC 2021

Colchicine in STEMI Fails to Reduce Infarct Size: COVERT-MI

August 26, 2021

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

August 31, 2020

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Under Pressure: PRECISION Substudy Shows Adverse BP Effects of Ibuprofen

News Conference News ESC 2017

Under Pressure: PRECISION Substudy Shows Adverse BP Effects of Ibuprofen

August 30, 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Presentation ESC 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Presenter: Paul M. Ridker

August 27, 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

NSAIDs Plus Anticoagulants a Bad Combination

September 01, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.